Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
PEPE Support Faces a Critical Technical Test

PEPE Support Faces a Critical Technical Test

CryptonewslandCryptonewsland2026/10/15 19:45
By:Cryptonewsland
  • PEPE is testing multi-month ascending support, with a decisive breakdown potentially exposing the token to additional selling pressure.
  • The 4-hour Stochastic RSI is in oversold territory and the weekly indicator is in oversold territory with high momentum from the recent recovery.
  • Descending resistance continues to constrain PEPE, leaving confirmation of a sustained bullish reversal dependent on price action around support.

Multi-month support nears a turning point for PEPE, a pivotal moment in its technical journey. It may make the difference between recovery by the buyer or further correction by the seller.

Multi-Month Support Becomes the Central Battleground

PEPE as of writing  trades near $0.00003861 in the referenced technical analysis. An ascending green trendline connects previous lows established during the summer recovery. Price has been erratic in its elevation, and is now moving toward this line.

The trendline is an area where buyers took selling pressure in the past. If demand does not keep up with supply, however, repeated testing can undermine support. A sustained defense would preserve the existing recovery structure without guaranteeing another rally.

Above the current price, descending trendlines continue restricting upward movement. These barriers connect lower highs formed during previous recovery attempts. Consequently, PEPE must overcome overhead resistance before establishing a more convincing bullish structure.

Momentum Indicators Present Conflicting Signals

The four hour Stochastic RSI indicator is trading around 7.79 and 21.39. These levels reflect poor short term momentum and the indicator is getting close to oversold. But such readings can’t say for certain that selling pressure is at its peak.

Any rally off of the higher level of support may ignite buying momentum again. However, traders would have to wait for stronger price action to confirm a recovery. Failure to attract buyers could leave PEPE vulnerable to another downward move.

The weekly chart provides a broader perspective on the token’s corrective structure. PEPE had significant gains in 2024, such as the fifth-wave peak. Rallies in the week since then failed to form a reversal of the overall downward movement.

The shorter time frame of weekly momentum shows a different picture. Stochastic RSI readings are close to 93.20 and 92.80, suggesting high momentum. Continued strength is possible with these readings, but a pullback is a possibility.

Breakout Confirmation Remains Essential

The weekly chart has a descending green trendline that is connecting lower highs. Meanwhile, a shorter descending black trendline guides the compressed pattern close to lower prices. Together, these boundaries frame the technical uncertainty surrounding PEPE’s next directional move.

The chart also presents an Elliott Wave interpretation suggesting a possible corrective wave C completion. That scenario anticipates a potential low before another recovery develops. However, wave counts remain interpretive and require confirmation from subsequent price action.

The recent intraday chart adds context to the support debate. PEPE dipped down to about $0.0000380 and bounced up significantly to $0.0000410. It has since rebounded to approximately $0.00004057, further evidence that resistance remains to hold any headway.

A break above the multi-month trendline would support a further recovery test. Any movement above descending resistance will be added confirmation of improving market structure. In the meantime, the rebound is still susceptible to further selling pressure.

Meanwhile, a major failure of the bulls would cast doubt on the current bull market. Such a move could expose PEPE to further losses and require reassessment of the proposed wave structure. For now, support defense and resistance clearance remain the principal technical tests.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Wall Street Stands Guard as Bessent Strikes Again: Aftereffects of August's "Treasury Turnaround" Persist, November Refinancing Notice Could Be the Next Flashpoint

As the US Treasury prepares to update its debt management plan in November, key clues may emerge on Friday.

智通财经•2026/10/16 01:06

"Coca-Cola belief" never goes out of style! KFC in America says goodbye to Pepsi and embraces Coca-Cola (KO.US); Buffett-style "boring investment" returns to the spotlight

KFC has chosen Coca-Cola as its soda supplier in the United States, abandoning its long-term partner Pepsi. As of the close of the U.S. stock market on Thursday, Coca-Cola's (KO.US) stock price reached a record high, defying the ongoing declines in global tech stocks, especially in the semiconductor and broad AI computing sectors.

智通财经•2026/10/16 01:06

AI financing concerns weigh heavily on chip stocks, global tech sector has lost over $1 trillion this week

Multiple pressures, including rising expectations of a Federal Reserve rate hike and increasing AI financing costs, have led to a massive sell-off in global tech stocks this week. The combined market value of the world's top 20 AI and semiconductor stocks has evaporated by more than $1 trillion, and the semiconductor ETF (SOXX) has recorded its longest losing streak in 11 years. On Thursday, SK Hynix continued to plunge by over 10% in a single day, while Nvidia, Samsung, and SoftBank were not spared.

华尔街见闻•2026/10/16 00:51

Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs

Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.

华尔街见闻•2026/10/16 00:37
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs